Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven ... 7thSpace Interactive (press release) Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% - 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed ... |
